Cardiovascular Disease

Study results from A.N. Phillips et al provide new insights into cardiovascular disease

Published in AIDS Weekly, June 2nd, 2008

"The SMART trial found a raised risk of cardiovascular disease (CVD) events in patients undergoing CD4(+) T cell-count guided intermittent antiretroviral therapy (ART) compared with patients on continuous ART. Exploratory analyses were performed to better understand the reasons for this observation," scientists in London, the United Kingdom report.

"A total of 5,472 patients with CD4(+) T-cell counts >350 cells/mm(3) were recruited and randomized to either continuous ART (the viral suppression arm; VS) or CD4(+) T-cell count-guided use of ART (the drug conservation arm; DC). Major CVD events developed in 79 patients. The hazard ratio (HR) for risk of CVD events for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2008-06-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry